Evotec and Bristol Myers Squibb: A Promising Neuroscience Collaboration

Evotec SE (EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Bristol Myers Squibb (NYSE: BMY) have made significant progress in their strategic neuroscience collaboration, with Evotec receiving a $20 million payment to advance a promising pre-clinical programme in neurodegeneration. This latest achievement underscores the strength of the partnership and its commitment to delivering innovative treatment options for patients suffering from neurodegenerative diseases.

The collaboration, initiated in December 2016, focuses on identifying disease-modifying treatments for a broad range of neurodegenerative diseases. While currently approved therapies primarily focus on symptom management, this partnership aims to develop transformative treatments that can slow or halt disease progression, addressing a significant unmet medical need. The collaboration has already yielded strong results, including the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. In March 2023, the companies reaffirmed their commitment by extending and expanding the collaboration for an additional eight years.

The $20 million payment to Evotec is a testament to the progress made in the collaboration and the potential of the pre-clinical programme in neurodegeneration. This funding will enable Evotec to further develop and advance the programme, bringing it one step closer to clinical development. The payment also reflects the shared mission of both companies to deliver truly innovative treatment options for patients suffering from neurodegenerative diseases.



The extended collaboration between Evotec and Bristol Myers Squibb is expected to yield more high-potential programmes advancing towards clinical development, further bolstering the joint pipeline in neurodegeneration research. This partnership is a prime example of how strategic collaborations between biotechnology companies and pharmaceutical giants can drive innovation and accelerate the development of transformative therapies for patients in need.

In conclusion, the latest progress in the neuroscience collaboration between Evotec and Bristol Myers Squibb highlights the potential of this strategic partnership in developing innovative treatments for neurodegenerative diseases. With the extended collaboration and the $20 million payment to Evotec, the partnership is well-positioned to continue making significant strides in the fight against these debilitating conditions.